Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Usage of human interferon in preparation of medicines for treatment or prevention of HPV (human paillomavirus) related diseases

A technology of interferon and interferon alpha, which is applied in the field of medicine to achieve the effect of enhancing the body's antiviral ability, inhibiting the virus, and having good clinical application prospects

Inactive Publication Date: 2012-08-01
ZHAOKE PHARMA HEFEI
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have also found that persistent HPV carriers strongly suggest that infected persons are at high risk of developing secondary precancerous lesions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Usage of human interferon in preparation of medicines for treatment or prevention of HPV (human paillomavirus) related diseases
  • Usage of human interferon in preparation of medicines for treatment or prevention of HPV (human paillomavirus) related diseases
  • Usage of human interferon in preparation of medicines for treatment or prevention of HPV (human paillomavirus) related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1, preparation prescription technology:

[0027] (1) Treatment of human interferon stock solution:

[0028] Add human serum albumin according to the volume of human interferon stock solution, so that the final concentration of human serum albumin is 5% (W / V), then add an equal volume of stabilizer SDS according to the total volume of the human interferon solution that has added albumin, Mix evenly, heat in a water bath for 0.5-3min, cool, divide and freeze-dry to powder.

[0029] (2) Matrix preparation:

[0030] Accurately weigh 200g of sodium carboxymethylcellulose, 500ml of glycerin, and 20g of sorbic acid, mix them, add water for injection to 10,000g, heat to 100°C and mix well, and when the matrix is ​​cooled to 40°C, adjust the pH to 7.5 and set aside.

[0031] (3) Preparation of human interferon preparation:

[0032]Add human interferon powder in the matrix (add human interferon powder 1.0 × 10 in every 1000g matrix 9 SI units), stirring constantly ...

Embodiment 2

[0033] Embodiment 2, preparation prescription process:

[0034] (1) Treatment of human interferon stock solution:

[0035] Add human serum albumin according to the volume of human interferon stock solution, so that the final concentration of human serum albumin is 1% (W / V), and then add an equal volume of stabilizer reduced form according to the total volume of the human interferon solution that has been added with albumin Glutathione, mixed evenly, heated in a water bath for 0.5 min, cooled, subpackaged and freeze-dried into powder.

[0036] (2) Matrix preparation:

[0037] Accurately weigh 50g of sodium carboxymethylcellulose, 1500ml of glycerin, and 10g of sorbic acid, mix them, add water for injection to 10,000g, heat to 60°C and mix well, and when the matrix is ​​cooled to 10°C, adjust the pH to 4.0 and set aside.

[0038] (3) Preparation of human interferon preparation:

[0039] Add human interferon powder in the matrix (add human interferon powder 1.0 × 10 in every 1...

Embodiment 3

[0040] Embodiment 3 preparation prescription technology:

[0041] (1) Treatment of human interferon stock solution:

[0042] Add human serum albumin according to the volume of the human interferon stock solution, so that the final concentration of human serum albumin is 3% (W / V), and then add an equal volume of stabilizer vitamin C according to the total volume of the human interferon solution that has been added with albumin , mixed evenly, heated in a water bath for 2 minutes, cooled, subpackaged and freeze-dried into powder.

[0043] (2) Matrix preparation:

[0044] Accurately weigh 100g of sodium carboxymethylcellulose, 750ml of glycerin, and 15g of sorbic acid, mix them, add water for injection to 10,000g, heat to 80°C and mix well, and when the matrix is ​​cooled to 30°C, adjust the pH to 9.5 and set aside.

[0045] (3) Preparation of human interferon preparation:

[0046] Add human interferon powder in the matrix (add human interferon powder 1.0 × 10 in every 1000g m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the medical field, and discloses the usage of human interferon in preparation of medicines for treatment or prevention of HPV (human paillomavirus) related diseases. According to clinical tests, human interferon has curative effects on HPV infection, and particularly has remarkable curative effects on simple type HPV infection and high-risk type HPV continuous genital tract infection. The usage of human interferon is significant to preventive treatment of HPV infection, particularly the simple type HPV infection, and prevention and reduction of cervical erosion and cervical cancers, and has bright clinical application prospect.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the use of human interferon in the preparation of medicines for treating HPV-related diseases. Background technique [0002] Cervical erosion is the most common clinical disease in gynecology and a common pathological change of chronic cervicitis. It is manifested as a fine-grained red area in the appearance of the cervicovaginal portion at the external os of the cervix. In recent years, studies at home and abroad have shown that human papillomavirus (HPV) infection is related to the pathogenesis of cervical erosion, and cervical HPV infection is the main cause of cervical cancer. Therefore, cervical erosion combined with HPV infection may develop into cervical cancer. The incidence of cervical cancer is closely related. Clinical studies have shown that HPV infection in patients with cervical erosion is related to the severity of local cervical lesions, whether it is combined with other...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/21A61P15/00A61P35/00A61P31/20A61P31/22A61P1/02A61P17/12
Inventor 李小羿张国辉戴向荣凌娟吴艳
Owner ZHAOKE PHARMA HEFEI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com